Cas:210113-91-0 ethyl 2-(3-cyanophenyl)acetate manufacturer & supplier

Chemical Name:ethyl 2-(3-cyanophenyl)acetate

CAS.NO:210113-91-0

Synonyms:(3-cyano-phenyl)-acetic acid ethyl ester;ethyl (3-cyanophenyl)acetate;AB3734

Molecular Formula:C₁₁H₁₁NO₂

Molecular Weight:189.21100

HS Code:2926909090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:50.09000

Exact Mass:189.07900

LogP:1.66388

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like (3-cyano-phenyl)-acetic acid ethyl ester chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,AB3734 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,ethyl (3-cyanophenyl)acetate Use and application,AB3734 technical grade,usp/ep/jp grade.

Related News: Developing countries such as China and India have good foundations for undertaking global industrial transfers because of their comparative advantages. With the continuous improvement of China’s fine chemical technology level, the types of products and market shares in China’s undertaking industrial transfer have gradually increased. ethyl 2-(3-cyanophenyl)acetate manufacturer Toxic forever chemicals have no place in personal care products,” Scott Faber, EWG’s senior vice president of government affairs. “PFAS have been linked to serious health problems, including cancer and harm to the reproductive and immune systems. EWG applauds Sen. Collins and Rep. Dingell for introducing the No PFAS in Cosmetics Act. ethyl 2-(3-cyanophenyl)acetate supplier Toxic forever chemicals have no place in personal care products,” Scott Faber, EWG’s senior vice president of government affairs. “PFAS have been linked to serious health problems, including cancer and harm to the reproductive and immune systems. EWG applauds Sen. Collins and Rep. Dingell for introducing the No PFAS in Cosmetics Act. ethyl 2-(3-cyanophenyl)acetate vendor From the perspective of the overall life cycle of generic drugs from R & D to sales, with the expiration of patents, the business model for the production and marketing of generic pharmaceutical raw materials has changed, demand has increased, business potential has been realized quickly, and gross profit margins have shown a downward trend. ethyl 2-(3-cyanophenyl)acetate factory Onconova is currently in the clinical development stage with oral and IV rigosertib, including clinical trials studying single agent IV rigosertib in second-line higher-risk MDS patients (pivotal Phase 3 INSPIRE trial) and oral rigosertib plus azacitidine in first-line and refractory higher-risk MDS patients (Phase 2).